

Special Issue

Metabolic Syndrome from the Perspectives of Genetics, Genomics and Proteomics

Message from the Guest Editors

Metabolic syndrome (MetS) is the cluster of various metabolic abnormalities that includes high blood glucose levels, hypertension, hyperlipidemia, abdominal obesity as well as low HDL levels sometimes. The World Health Organization illustrates that the presence of three or more of these metabolic abnormalities constitutes metabolic syndrome. According to data from the IDF Atlas, global prevalence of diabetes—which is the highest contributor towards MetS—is at 8.8% and is only increasing; MetS, which is more than three times more common than diabetes itself, can be estimated to affect 25% of the world population. Recent advancements in genetics and genomics approaches have allowed us to better understand metabolic diseases. For example, recent genome-wide association studies (GWAS) have identified many new loci and genes associated with BMI and blood glucose levels. Moreover, advanced genomics and other multi-omics approaches have enabled us to study these new loci and genes more robustly in a high-throughput manner.

Guest Editors

Dr. Gautam Kumar Pandey

Department of Genetics, University of North Carolina, Chapel Hill, NC, USA

Dr. Prabu Paramasivam

Department of Neurology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA

Deadline for manuscript submissions

closed (31 July 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/179994

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).